Oversight of Clinical Investigations: A RiskBased Approach to Monitoring (Draft Guidance) U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluatio

First Page		Document Content
Pharmaceutical industry Pharmacology Food and Drug Administration Clinical trial Clinical investigator Regulatory requirement Good Clinical Practice Center for Drug Evaluation and Research Good Clinical Data Management Practice Clinical research Research Pharmaceutical sciences		Oversight of Clinical Investigations: A RiskBased Approach to Monitoring (Draft Guidance) U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluatio Add to Reading List Source URL: www.fda.gov. Download Document from Source Website File Size: 525,67 KB Share Document on Facebook

	Data Integrity and Compliance With CGMP Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. DocID: 1q6Px - View Document
	p-medicine – Grant Agreement noD2.1 – State of the art review of the p-medicine environment Deliverable No. 2.1 State of the art review of the p-medicine environment DocID: 1q1lq - View Document
	GOOD PRACTICE PRINCIPLES FOR SHARING INDIVIDUAL PARTICIPANT DATA FROM PUBLICLY FUNDED CLINICAL TRIALS DocID: 1owuq - View Document
	In the Patient’s Interest: Improving Access to Clinical Trial Data August 2014 Prepared by: Brenda J. Huneycutt, PhD, JD, MPH; DocID: 15nq8 - View Document
	PRESS RELEASE Lisbon, Portugal, November 2014 The International Conference on Harmonisation (ICH) Steering Committee (SC) and its Expert Working Groups (EWGs) met in Lisbon, Portugal, EU on November 8 – 13, 2014. The m DocID: 155Gq - View Document